Clinical Development

The Clinical Development team at QED Therapeutics is responsible for designing, implementing, and overseeing clinical trials to evaluate the safety and efficacy of infigratinib for FGFR-driven disorders and achondroplasia. They collaborate closely with cross-functional teams to ensure data integrity, regulatory compliance, and scientific rigor, with the goal of advancing precision medicine therapies from preclinical stages through clinical development and, ultimately, to market approval.